Viking Therapeutics (VKTX) is under pressure as it prepares to release its Q1 2026 earnings on April 29, amid projections of a staggering 151.27% decline in EPS year-over-year and a substantial net loss from the previous quarter. Despite these financial troubles, analysts remain optimistic, maintaining strong buy ratings and forecasting a potential stock price increase of over 20%, driven by anticipation of positive outcomes from their obesity drug trials. With the completion of patient enrollment in the Phase 3 VANQUISH-2 trial and the development of GLP-1-based therapies, Viking stands at a crucial juncture that could redefine its market trajectory.
“Agreed—scaling water bomber output (CL-415/NextGen successors via Viking or partners) directly monetizes Canadian aerospace expertise. Global wildfire seasons drive real export demand; backlog lists from US, EU, Australia already exist, with each unit $25-40M+.”
“AI-optimized assembly + transparent grants/loans could double production rates without debt spike, adding $1-2B+ annual revenue by 2030 while protecting domestic forests/resources.”
“The most followed narrative for Viking Therapeutics points to a fair value of $92.72 per share compared with the last close at $35.20. The gap between price and narrative fair value is substantial and built on specific views about future obesity treatments and earnings power.”
“Smaller biotechs like Viking Therapeutics VKTX are also developing GLP-1-based therapies to challenge the incumbents. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity.”
“Given the mix of optimism around obesity treatments and concern about valuation and funding, this is a moment to move quickly and test the numbers yourself, then weigh the 1 key reward and 2 important warning signs.”
“Old Second Bancorp, Inc. Reports First Quarter 2026 Net Income of $25.6 Million, or $0.48 per Diluted Share”
“DraftKings to Release First Quarter 2026 Results on May 7, 2026 and Host Conference Call on May 8, 2026”
“Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026”
“Analyst sees GLP-1/GIP data readthrough as neutral-to-positive, with no meaningful LBM disadvantage and stronger weight loss profile supporting VKTX outlook.”
“Company has been rated SELL since 06/29/15. The Company's Fundamentals Look Very Poor Making an Investment in Its Shares Purely Speculative.”
“Average price target from 19 ratings: $93.59.”
“VKTX will report Q1 2026 earnings on 04/29/2026.”